medigraphic.com

2008, Number 3

<< Back Next >>

Arch Cardiol Mex 2008; 78 (3)

Alteplase in acute coronary syndromes

Iturbe OM, Jerjes-Sánchez DC, García-Sosa A, García H, Reyes CE, Fernández D, Garza RA, Assad C, Castillo F, González M, García J, Valadéz F, Chávez M, Garza O

Language: Spanish
References: 26
Page: 255-264
PDF size: 155.07 Kb.


ABSTRACT

Objective: The registry intends to establish the safety and security of one-hour 100 mg alteplase infusion and 50 mg in 30 minutes to facilitate percutaneous coronary intervention (PCI) in a cardiology hospital with primary angioplasty program (24 hours 365 days a year) with current doses of unfractionated heparin and enoxaparin. Methods and results: REALSICA II is a prospective registry that included 103 patients with final diagnosis of ST elevation myocardial infarction in which Alpert´s quality criteria were used. Seventy two patients were under one-hour 100 mg alteplase infusion and thirty one under 30 minutes 50 mg alteplase infusion to facilitate PCI. Patients were young and predominantly males. In both groups › 50% had extensive ST elevation myocardial infarction and 68% were Killip & Kimball I. The majority received reperfusion › 3 hours after the onset of symptoms. In-hospital and follow-up treatment were compliant with Mexican Cardiology Society guidelines. ECG reperfusion was observed in 59% and TIMI III flow in 19% of PCI group. Any intracranial hemorrhage was observed. Global cardiovascular mortality was 11%. Patients under PCI had low incidence of recurrent ischemia and reinfarction. Conclusion: REALSICA registry showed in non- complicate acute myocardial infarction ST elevation safety and security of one – hour 100 mg alteplase infusion with current recommended unfractionated heparin and enoxaparin doses in ST elevation myocardial infarction. In complicated patients the regimen to facilitate PCI was associated with increased hemorrhagic complications and requires further research.


REFERENCES

  1. Por el Grupo Cooperativo RENASICA. El Registro Nacional de los Síndromes Isquémicos Coronarios Agudos. (RENASICA) Sociedad Mexicana de Cardiología. Arch Cardiol Mex 2002; 72: S45-S64.

  2. Garcia A, Jerjes-Sanchez C, Martinez BP, Azpiri-Lopez JR, Autrey CA, Martinez SC, et al, por los Investigadores del Registro Nacional de Síndromes Coronarios Agudos II: Renasica II. Un registro Mexicano de síndromes coronarios agudos. Arch Cardiol Mex 2005; 75(Supl 2): S6-S19.

  3. Jerjes-Sánchez C, Del Ángel SE, García SA, Reyes CE, Garza RA: Estrategias para mejorar la reperfusión con terapia fibrinolítica en infarto con elevación del ST. Arch Cardiol Mex 2003; 73: 46-58

  4. Jerjes-Sánchez C, Garza-Ruiz A, Gutiérrez-Fajardo: Trombólisis farmacológica en el infarto agudo del miocardio: lecciones aprendidas después del ISIS-2 y GUSTO I. (Parte I). Arch Inst Cardiol Mex 1999; 69: 478-487.

  5. Jerjes-Sánchez C, Garza-Ruiz A, Gutiérrez-Fajardo: Trombólisis farmacológica en el infarto agudo del miocardio: lecciones aprendidas después del ISIS-2 y GUSTO I. (Parte II). Arch Inst Cardiol Mex 1999; 69: 570-579.

  6. Martínez SC, Domínguez JL, Aguirre SJ, Carrillo J, Chuquiure VE, Franco J, et al: Tratamiento del infarto agudo al miocardio con rt-PA en 60 minutos. Estudio Cooperativo. Arch Inst Cardiol Mex 1997; 67: 126-131.

  7. Gulba DC, Tanswell P, Dechend R, Sosada M, Weis A, Waigand J, et al: Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1611-1617.

  8. Assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention investigators. Primary versus tenecteplasa – facilitated percutaneous coronary intervention in patients with ST- segment elevation acute myocardial infarction (ASSENT – 4 PCI): randomized trial. Lancet 2006; 367: 569-578.

  9. Simmons ML, Krzemiñska-Pakula M, Alonso A, Goodman SG, Kali A, Loss U, et al, for the AMI-SK investigators: Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. Eur Heart J 2002; 23: 1282-1290.

  10. Antman EM, Morrow DA, McCabe CH, Murhpy SA, Ruda M, Sadowski Z, et al, for the ExTRACT – TIMI 25 Investigators: Enoxaparin versus unfractionated heparin with fibrinolysis for ST – elevation myocardial infarction. N Engl J Med 2006; 354: 1-12.

  11. Jerjes-Sánchez C, Garza-Ruiz A, Gutiérrez-Fajardo P, Villarreal CG: Nuevas estrategias para la estratificación y tratamiento de los síndromes isquémicos coronarios agudos. Una propuesta. Arch Inst Cardiol Mex 1999; 69: 163-175.

  12. Jerjes-Sánchez C, Comparán A, Canseco-Ávila LM, Garza-Ruiz A, García-Sosa A, Reyes-Cerezo E: Marcadores en la estratificación de los síndromes coronarios agudos. Arch Cardiol Mex 2006; 76: S2, 241-248.

  13. Comparán A, Palacios JM, Jerjes-Sánchez C: Leucocitos y su asociación con eventos cardiovasculares adversos en infarto con elevación del ST sometidos a intervención coronaria percutánea. Arch Cardiol Mex 2005; 75(Supl 3): S61-S68.

  14. Alpert JS: Are data from clinical registries of any value? Eur Heart J 2000; 21: 1399-1401.

  15. Bertrand ME, McFadden EP: Late is perhaps not….too late for primary PCI in acute myocardial infarction. Eur Heart J 2002; 23: 550-557.

  16. Nallamothu BK, Bates ER: Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003; 92: 824-826.

  17. Martínez-Ríos M, Rosas M, González H, Peña-Duque MA, Martínez-Sánchez C, Gaspar J, et al, for the SASTRE Investigators: Comparison of reperfusion regimens with or without tirofiban in ST elevation acute myocardial infarction. Am J Cardiol 2004; 93: 280-287.

  18. García A, Jerjes-Sánchez C, Martínez SC, Llamas EG, Cardona E, Barragán R, et al, por el Grupo de Trabajo de la Sociedad Mexicana de Cardiología y la Asociación de Cardiólogos de México: Guías clínicas para el manejo del infarto agudo del miocardio con elevación del segmento ST. Arch Cardiol Mex 2006; 76(S3): 1-113.

  19. Foussas SG, Zairis MN, Lyras AG, Patsourakos NG, Tsirimpis VG, Katsaros K, et al: Early prognostic usefulness of C-reactive protein added to the thrombolysis in myocardial infarction risk score in acute coronary syndromes. Am J Cardiol 2005; 96: 533-537.

  20. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalesco G, Theroux P, et al: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST- segment elevation. N Engl J Med 2005; 352: 1179-1189.

  21. Scirica BN, Sabatine MC, Morrow DA, Gibson MC, Murphy SA, Wiviott SD, et al: The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST segment elevation myocardial infarction. The ECG CLARITY – TIMI 28 study. J Am Coll Cardiol 2006; 48: 37-42.

  22. Zeymer U, Gitt AK, Jünger C, Heer T, Wienberger H, Koeth O, et al: Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST – segment elevation myocardial infarction in clinical practice. Eur Heart J 2006; 27: 2661-2666.

  23. Wong CK, Stewart RAH, Gao W, French JK, Raffel C, White HD, for the hirulog and early reperfusion or Occlusion (HERO – 2) trial investigators: Prognostic differences between different types of bundle branch block during early phase of acute myocardial infarction: insights from the Hirulog and Early Reperfusion or Occlusion (HERO – 2) trial. Eur Heart J 2006; 27: 21-28.

  24. Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin ML, Williams DO, et al, for the Atlantic Cardiovascular Patient Outcomes Research Team: Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: A randomized controlled trial. JAMA 2002; 287: 1943-1951.

  25. Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, et al: Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 2005; 27: 1971-1977.

  26. Thiele H, Engelmann L, Elsner K, Kappl MJ, Storch WH, Rahimi K, et al, for the Leipzig Prehospital Fibrinolysis Group: Comparison of pre-hospital combination -fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005; 26: 1956-1963.




2020     |     www.medigraphic.com